News
Deep learning AI predicts response to cancer treatment
Artificial intelligence software developed by Pangea Biomed can …
19713 items found
News
UK gets guidance on synthetic human embryos for research
A new code of practice has been drawn up in the UK to try to make …
News
Roche’s TIGIT drug linked to worse outcomes in NSCLC trial
Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, …
News
Study links Ozempic/Wegovy to sight-threatening disorder
Shares in Novo Nordisk and Eli Lilly have been under pressure after a …
Oncology
Top cancer types, trials, and AI innovations: What HCPs discussed most at ASCO 2024
Kicking off in Chicago on the 31st May, the 2024 American Society of …
Oncology
The fire and ice of oncolytic virotherapy
In the language of immuno-oncology (IO), the terms “hot” and “cold” …
Oncology
News
Beacon lights up with $170m for retinal disease gene therapy
UK-headquartered Beacon Therapeutics has raised a whopping $170 …
News
GSK goes all-in on CureVac’s mRNA vaccines
GSK has upgraded its longstanding alliance with CureVac on mRNA-based …
News
EU first to approve Dupixent for COPD
Chronic obstructive pulmonary disease (COPD) has seen no new …
Sales & Marketing
Sponsored
Frontiers Health 2024: The foundational pillars
Frontiers Health, a key player in health innovation, has announced …
News
Advantage J&J in multiple myeloma CAR-T tussle with BMS
Johnson & Johnson and partner Legend Biotech are celebrating a big …
News
Lilly's Alzheimer's drug gets UK nod, but no NHS funding
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NI
Sales & Marketing
Enabling site success: Key insights to reducing burden and i...
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
R&D
LSX 2024 - Dr Tadaaki Taniguchi
At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some r
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
R&D
Partner Content
8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
